Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
